title: Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines.
authors: Therion Biologics Corporation, Cambridge, MA 02142.
authors: D L
authors: DL
authors: Panicali
authors: G
authors: G
authors: Mazzara
authors: J L
authors: JL
authors: Sullivan
authors: R
authors: R
authors: Hesselton
authors: L
authors: L
authors: Shen
authors: N
authors: N
authors: Letvin
authors: M
authors: M
authors: Daniel
authors: R
authors: R
authors: Desrosiers
authors: E J
authors: EJ
authors: Stott
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D005814:Genes, Viral; D005822:Genetic Vectors; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007111:Immunity, Cellular; D008251:Macaca; D011817:Rabbits; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines